Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04202497 · ClinicalTrials.gov registry record · Phase 1
A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04202497 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 7 participants.
The verdict
NCT04202497, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine brain LSD1 enzyme occupancy and the relationship of occupancy to TAK-418 dose and plasma exposure after single oral dosing of TAK-418 in healthy participants using \[18F\]MNI-1054 positron emission tomography (PET) imaging.
Interventions
- DRUG TAK-418
- DRUG [18F]MNI-1054 (radiotracer)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2020-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04202497
The ClinicalTrials.gov registry entry for NCT04202497 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-418 is the first listed.
NCT04202497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04202497 about?
NCT04202497 is a clinical study titled "A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants". The purpose of this study is to determine brain LSD1 enzyme occupancy and the relationship of occupancy to TAK-418 dose and plasma exposure after single oral dosing of TAK-418 in healthy participants using \[18F\]MNI-1054 positron emission tomography (PET) imaging.
What is the current status of trial NCT04202497?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-12-18. Estimated completion is 2020-03-19.
What interventions are being tested in trial NCT04202497?
The interventions under investigation include: TAK-418 (DRUG), [18F]MNI-1054 (radiotracer) (DRUG).
Who is sponsoring clinical trial NCT04202497?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.